The 8 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 30.00, with a high estimate of 55.00 and a low estimate of 22.00. The median estimate represents a +248.43% increase from the last price of 8.61.
The current consensus among 8 polled investment analysts is to Buy stock in EyePoint Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.69
Reporting Date Nov 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.